A Note on Peptides by Shantanu Out of Singapore FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling BPC 157 Banned: Key Facts on the Latest FDA Decision BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved